Nasdaq:EKSO
EKSO BIONICS HOLDINGS, INC.
EKSO develops autonomous robotic exoskeletons designed to restore mobility for patients with severe neurological injuries.
Key Metrics
Investment Thesis
Bull Case
EKSO operates in the high-growth field of regenerative medicine and assistive technology, where early adopters can capture significant market share before competitors mature. The company's deep technical moat in autonomous control systems provides a unique value proposition that few incumbents can easily replicate without massive R&D investment. If the company successfully scales its commercialization efforts to match its research breakthroughs, the current valuation could reflect substantial upside potential driven by expanding reimbursement coverage.
Bear Case
The company has posted consistent net losses exceeding $10M annually over the last five years, with a retained earnings deficit of $-262.4M that raises concerns about long-term capital sustainability. Revenue contraction in the most recent period from 2023 to 2025 signals potential fragility in its go-to-market strategy or an inability to convert clinical success into commercial scale. Investors should be wary of the dilution risk associated with common share issuances totaling $4.1M recently, which could further depress shareholder value if profitability is not achieved quickly.
About EKSO BIONICS HOLDINGS, INC.
EKSO Bionics Holdings develops advanced robotic exoskeletons designed to restore mobility and independence for individuals with spinal cord injuries, stroke survivors, and other mobility impairments. The company primarily serves the medical device and rehabilitation markets in North America, Europe, and Asia through direct patient access and specialized clinical partnerships. Its flagship product line includes wearable robotic systems that leverage proprietary control algorithms to enable functional movement.
Analysis
Management Discussion
Despite a 35% year-over-year revenue growth from $12.9M in 2022 to $18.3M in 2023, the company's net income remained negative at $-11.7M for the latest period, indicating ongoing high burn rates typical of deep-tech medical startups. The recent decline in revenue from $18.3M in 2023 to $12.8M in 2025 suggests potential market saturation or pricing pressures that management must address through improved operational efficiency or new product launches. While cash flow from financing activities provided $6.6M in support, the operating cash flow of -$11.8M highlights the critical need for sustained capital raises or a clear path to profitability.
Industry Overview
The robotic exoskeleton market is evolving rapidly as a bridge between traditional physical therapy and advanced assistive technology, driven by an aging population and increased focus on rehabilitation outcomes. While currently a niche sector dominated by specialized startups, the industry is attracting attention from major medical conglomerates seeking to diversify their portfolios with innovative mobility solutions. Regulatory landscapes are shifting toward greater reimbursement support for robotic devices, potentially accelerating adoption rates across developed healthcare systems.
Financial Statements
Income Statement
Balance Sheet
Cash Flow
| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Revenue | $12.9M | $18.3M | $17.9M | $12.8M |
| Cost of Revenue | $6.7M | $9.2M | $8.4M | $6.0M |
| Gross Profit | $6.2M | $9.1M | $9.5M | $6.8M |
| Operating Expenses | $21.8M | $24.2M | $20.0M | $20.2M |
| Operating Income | $-15.6M | $-15.1M | $-10.5M | $-13.3M |
| R&D | $3.6M | $5.0M | $3.9M | $3.0M |
| G&A | $11.0M | $10.7M | $8.8M | $10.0M |
| Marketing | $7.2M | $8.5M | $7.3M | $7.2M |
| Stock-Based Comp | $2.5M | $1.9M | $1.4M | $1.5M |
| D&A | $887.0K | $1.7M | $1.6M | $1.6M |
| Depreciation | $486.0K | $726.0K | $658.0K | $563.0K |
| Other OpEx | $0 | $0 | $0 | $0 |
| Non-Operating Income | $476.0K | $-86.0K | $-870.0K | $1.6M |
| Interest Expense | $156.0K | $302.0K | — | — |
| Pre-Tax Income | $-15.1M | $-15.2M | $-11.3M | $-11.7M |
| Income Tax | $0 | $0 | $0 | $0 |
| Continuing Ops | $-15.1M | $-15.2M | $-11.3M | $-11.7M |
| Discontinued Ops | $0 | $0 | $0 | $0 |
| Net Income | $-15.1M | $-15.2M | $-11.3M | $-11.7M |
| Minority Interest | $0 | $0 | $0 | $0 |
| Net to Common | $-15.1M | $-15.2M | $-11.3M | $-11.7M |
| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Current Assets | $31.0M | $20.2M | $18.8M | $14.0M |
| Cash & Equivalents | $20.5M | $8.6M | $6.5M | $1.2M |
| Accounts Receivable | $4.6M | $5.6M | $7.2M | $7.3M |
| Inventory | $5.2M | $5.0M | $4.6M | $4.8M |
| Prepaid Expenses | $700.0K | $875.0K | $541.0K | $750.0K |
| Other Current Assets | $0 | $0 | $0 | $0 |
| Long-Term Assets | $9.9M | $8.7M | $7.8M | $6.1M |
| PP&E (Net) | $2.7M | $2.0M | $1.6M | $1.3M |
| Intangibles | $5.2M | $4.9M | $4.6M | $3.5M |
| Goodwill | $431.0K | $431.0K | $431.0K | $431.0K |
| Operating Leases | $1.3M | $977.0K | $788.0K | $532.0K |
| Other LT Assets | $231.0K | $392.0K | $433.0K | $311.0K |
| Total Assets | $40.9M | $28.9M | $26.7M | $20.1M |
| Current Liabilities | $9.2M | $8.1M | $7.5M | $8.6M |
| Accounts Payable | $3.2M | $1.8M | $1.6M | $1.4M |
| Current Leases | $341.0K | $363.0K | $427.0K | $441.0K |
| Deferred Revenue | $1.1M | $2.0M | $2.0M | $1.7M |
| Other Current Liab | $2.3M | $1.2M | $1.2M | $3.3M |
| Long-Term Liabilities | $6.3M | $8.2M | $6.4M | $2.4M |
| LT Operating Leases | $1.1M | $723.0K | $452.0K | $147.0K |
| Other LT Liab | $4.1M | $5.3M | $4.0M | $887.0K |
| Total Liabilities | $15.5M | $16.3M | $13.9M | $11.1M |
| Shareholders' Equity | $25.4M | $12.6M | $12.7M | $9.0M |
| Paid-In Capital | $248.8M | $251.6M | $262.2M | $272.1M |
| Retained Earnings | $-223.9M | $-239.1M | $-250.5M | $-262.4M |
| AOCI | $563.0K | $156.0K | $957.0K | $-692.0K |
| Total L&E | $40.9M | $28.9M | $26.7M | $20.1M |
| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Net Income (CFO) | $-15.1M | $-15.2M | $-11.3M | $-11.7M |
| Non-Cash Adjustments | $-568.0K | $1.5M | $1.2M | $1.9M |
| Working Capital Changes | $960.0K | $1.7M | $237.0K | $-2.0M |
| Cash from Operations | $-14.7M | $-12.1M | $-9.8M | $-11.8M |
| Capital Expenditures | $194.0K | $157.0K | $37.0K | $188.0K |
| Cash from Investing | $-5.2M | $-157.0K | $-37.0K | $-188.0K |
| Cash from Financing | $0 | $348.0K | $7.8M | $6.6M |
| FX Effect | $-18.0K | $-24.0K | $-31.0K | $36.0K |
| Net Change in Cash | $-19.9M | $-11.9M | $-2.1M | $-5.3M |
| Beginning Cash | $40.4M | $20.5M | $8.6M | $6.5M |
| Ending Cash | $20.5M | $8.6M | $6.5M | $1.2M |
Frequently Asked Questions
How does EKSO BIONICS HOLDINGS, INC. make money?
The company's revenue is derived from the sale of its EKSO-NX and other robotic exoskeleton hardware units, as well as associated consumables such as batteries and charging stations. Revenue also includes licensing fees and royalties generated from strategic partnerships with healthcare systems and research institutions that utilize the technology for patient rehabilitation.
What are the main risks for EKSO?
The company faces significant commercialization risks as it transitions from a research-focused entity to a revenue-generating business with limited current profitability. High competition from established medical device giants and emerging biotech startups could erode market share if the company fails to maintain its technological edge or pricing power. Regulatory hurdles in various international markets, including FDA clearance processes and varying reimbursement policies, pose potential delays to global expansion.
What is EKSO's competitive advantage?
EKSO holds strong intellectual property protection through a robust portfolio of patents covering its unique control algorithms and mechanical designs for autonomous movement. The company benefits from first-mover advantages in specific high-value niches within the spinal cord injury community, fostering deep loyalty among patient advocacy groups. Its proprietary software allows for rapid adaptation to individual patient needs, reducing reliance on extensive manual therapy sessions.
Related Companies
Not financial advice. All content is for informational purposes only. Data may contain errors. Consult a qualified financial advisor before making investment decisions.